Please don't ask me why I support BIG and its breast cancer research...
yourself why you don't...
Many take for granted that breast cancer can be cured, with diminishing donations as a result. But the disease still kills, and donations save lives.
Donations save lives by making it possible to carry out research that otherwise could not be done, research addressing specific problems that remains poorly or not at all funded by pharmaceutical companies.
Meanwhile, we feel the absence of those we have lost. By financing research, we work to save individuals and help keep families intact.
What is MISSING?
Breast cancer is the most commonly diagnosed cancer in the world, with Belgium having the highest incidence worldwide.
People were diagnosed with
breast cancer in 2020.
1 in 4
Of all new cancer cases
in women worldwide.
1 in 800
For men, the lifetime risk of
developing breast cancer.
±100 000 Patients have participated in BIG trials. Patients are at the heart of BIG’s research
±60 Academic research groups makeup the largest international network dedicated solely to breast cancer research.
±10 000 Breast cancer specialists work within the BIG network.
>30 Patient-centred clinical trials andresearch programmes are rununder the BIG umbrella at any onetime.
Saving lives and improving care for over 20 years
not-for-profit organisation that represents the largest network of academic research groups dedicated to finding better treatments and cures for breast cancer.
BIG is focused on today's research, for tomorrow's cures.
After breast-conserving surgery, higher radiation doses to the part of the breast where ductal carcinoma in situ (DCIS) was found, in addition to radiotherapy of the whole breast, significantly reduced recurrence in higher risk patients. Radiotherapy could also be shortened safely.
The latest analysis showed the use of anti-HER2 therapy adding pertuzumab to trastuzumab and chemotherapy resulted in a 28% reduction in the risk of recurrence or death for those patients with HER2+ early breast cancer at highest risk, such as those with lymph node-positive disease.
SOFT & TEXT
Relapse rates could be cut by 34% thanks to a new treatment option combining exemestane with ovarian function suppression for young women with breast cancer.